Alzheimer's disease (AD) is a progressive neurodegenerative condition in which aggregated tau and amyloid proteins accumulate in the brain causing neuronal dysfunction which eventually leads to cognitive decline. Hyperphosphorylated tau aggregates in the neuron are believed to cause most of the pathology associated with AD. These aggregates are assumed to be released into the extracellular compartment and taken up by adjacent healthy neurons where they induce further tau aggregation. This "prion-like" spreading can be interrupted by antibodies capable of binding and "neutralizing" extracellular tau aggregates as shown in preclinical mouse models of AD. One of the proposed mechanisms by which therapeutic antibodies reduce pathology is antibody-mediated uptake and clearance of pathological aggregated forms of tau by microglia. Here, we describe a quantitative cell-based assay to assess tau uptake by microglia. This assay uses the mouse microglial cell line BV-2, allows for high specificity, low variability and medium throughput. Data generated with this assay can contribute to a better characterization of anti-tau antibody effector functions.
Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative condition characterized by the conformational change and self-assembly of amyloid β peptide and tau protein into pathological aggregates. The normal soluble amyloid β peptide is converted into oligomeric and fibrillar amyloid β, while abnormally phosphorylated tau accumulates as oligomers and neurofibrillary tangles 1, 2 . These protein aggregates cause neuronal death leading to memory loss and subsequent progressive cognitive decline. Other factors, including non-productive neuroinflammation and a reduced ability to clear misfolded proteins, may exacerbate and accelerate disease. Currently, intervention strategies against AD provide largely symptomatic relief, but there is no disease-modifying cure or prevention.
Increasing evidence suggests a key role of hyperphosphorylated tau aggregates in the pathology of AD. In its non-pathological state, tau is a natively unfolded protein that binds to microtubules and promotes their assembly into the neuronal cytoskeleton. When tau becomes hyperphosphorylated, it detaches from the cytoskeleton and clusters into tau aggregates in the neuron, which are believed to cause most of the pathology associated with AD 3 . Aggregated tau starts accumulating first intracellularly, but as disease progresses, it is assumed to be released from affected neurons into the extracellular space, from which it can be taken up by adjacent or synaptically connected healthy neurons in a "prion-like manner". Once internalized, the tau aggregate induces further tau aggregation via templated conformational change 4 
.
According to this hypothesis, therapies capable of interrupting tau seeding might slow down or reverse the course of tau-mediated neurodegenerative disease. In support of this, mice made susceptible to tauopathy by genetic mutation and passively injected with anti-tau antibodies show reduced tau pathology and improved cognitive function 5, 6, 7, 8, 9 . However, the mechanisms by which therapeutic antibodies reduce pathology still remain elusive.
One of the proposed mechanisms is antibody-mediated uptake and clearance of pathological aggregated forms of tau by microglia, the brain's resident immune cells. Recent publications suggest that microglia can efficiently internalize and degrade pathological tau species and this ability is enhanced by anti-tau antibodies via an Fc-dependent mechanism involving Fc receptors expressed on the surface of microglia and receptor mediated phagocytosis
Protocol

BV-2 Cells Culture
NOTE: Handle BV-2 cells under Biosafety Level 2 containment. The BV-2 cell line produces an enveloped recombinant ecotropic retrovirus (capable of infecting murine cells only) 12 ; such viruses are known for their in vitro transforming ability and in vivo tumorigenic potential.
1. Culture BV-2 cells in high glucose Dulbecco's modified eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 µg/mL streptomycin and 2 mM L-Glutamine (referred to as culturing medium from now on) by seeding cells at 4 x 10 4 cells/mL.
2. Maintain cultures in a humidified atmosphere of 5% CO 2 at 37 °C. NOTE: the cells grow loosely attached and in suspension.
Label Recombinant Tau Aggregates with pH-sensitive Fluorescent Dye
NOTE: Tau aggregates were prepared as described in Apetri et al. 13 with the difference that no Thioflavin T (ThT) was added to the reaction buffer. Aggregated samples were collected in 1.5 mL centrifuge tubes. Final fluorescence signal was checked by mixing 118 µL of the pool sample with 12 µL of a 50 µM ThT solution. Aggregates were separated by centrifuging the aggregation reaction mixture at 20,000 x g for 1 h at 4 °C. The supernatant was analyzed by SEC-MALS to confirm that all the monomeric tau was converted into aggregates. Pellets (tau aggregates) were snap frozen and stored in a freezer at -80 °C. . 2. Sonicate the resuspended aggregates using a probe sonicator while keeping on ice to avoid over-heating.
1. Use an amplitude of 65% (with sonicator of power 250 W).
Perform 8 pulses of 3 s with pauses of 15 s between pulses to avoid overheating.
3. Prepare an 8.9 mM stock solution of pH-sensitive dye (henceforth reference to as pH dye) in dimethyl sulfoxide (DMSO) following manufacturer's instruction. Note: Always prepare a fresh solution and use it only on the day it is prepared. 4. Add 10 moles of dye per mole of protein to a final dye concentration of 0.2 mM. 5. Mix by gently pipetting up and down. 6. Incubate the reaction mixture for 45-60 min at room temperature, protected from light. 7. In the meantime, assemble a cross-linked dextran gel desalting column following manufacturer's instructions. 8. Equilibrate the column with 25 mL of 0.1 M NaHCO 3 buffer pH 8.5 containing 3% DMSO. Discard the flow through. 9. Add the product of the tau aggregate labeling reaction to the column in a total volume of 2.5 mL. If the sample is less than 2.5 mL, add buffer until a total volume of 2.5 mL is achieved. 10. Let the sample enter the packed gel completely, discard the flow-through. 11. Elute with 3.5 mL of 0.1 M NaHCO 3 buffer pH 8.5 containing 3% DMSO and collect the eluate in 4 equivalent fractions in 2 mL tubes. 12. Determine protein concentrations of the 4 fractions by bicinchoninic acid (BCA) assay. 13. Store the labeled protein in a -20 °C freezer.
Uptake Assay with Fluorescence-activated Cell Sorting (FACS) Read-out
. Moreover, they showed a reproducible behavior in vitro which made them highly suitable for assay development and quantitative studies, which require minimal experimental variability. Beside this, immortalized cell lines allow higher assay throughput and eliminate the need for animal sacrifice compared to the use of primary microglia.
The tau aggregates we used in this assay were obtained using the highly reproducible in vitro aggregation procedure that we recently described 13 , and show similar morphology to paired helical filaments (PHFs) isolated from brains of AD patients. While we did not observe any unexpected results that might have been caused by tau aggregates adherence to plastic or glass surfaces, the use of stable and well characterized tau aggregates played a crucial role in the reproducibility of this assay.
Another aspect that significantly contributed to assay reproducibility was cell density. The numbers of cells per well described in the protocol represent the optimal cell density in the described conditions. Differently than what Funk et al. 11 described, we labeled tau aggregates with a pH sensitive dye which significantly increases its fluorescence upon internalization in acidic organelles, thus allowing for intracellular quantification. This, together with trypsin digestion of surface bound immunocomplexes and/or tau, guarantees that fluorescence signal measured by flow cytometry is the result of tau uptake rather than binding to the cellular surface. Moreover, the use of a pH sensitive dye eases detection of internalized tau aggregates in microscopy experiments without the need of digesting surface bound immunocomplexes/tau aggregates which would then requires cell re-plating and recovery.
We also further optimized the microscopy read-out of our assay, compared to what has previously been described 11 , by using a highly selective dye for acidic organelles in our microscopy experiments which allowed us not only to confirm antibody-mediated tau uptake, but also localization of tau aggregates in the endolysosomal compartment.
The assay we developed, has optimal specificity which results in a good experimental window allowing a strong separation between positive and negative samples. Interestingly, the assay indirectly detects differences in antibody affinity thus representing a powerful tool to study anti-tau antibody effector functions.
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